Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple Ascending Oral Doses of OPC-39436 in Healthy Elderly Subjects
jRCT2080222928Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of OPC-39436 (3 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Safety and tolerability of OPC-39436 multiple oral doses and Pharmacokinetics of OPC-39436. Started Jul 2015; status: completed.
02
Drugs
OPC-39436
Beyond the preview
Go deeper on jRCT2080222928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222928.